Self-administration of rozanolixizumab, a neonatal Fc receptor blocker (FcRn) indicated for generalized myasthenia gravis, ...

RemeGen has submitted a Biologics License Application (BLA) to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for IgAN, which if approved would ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Vor Biopharma Inc (VOR-Q) from The Globe and Mail including charting and trades.

Myasthenia gravis is a rare disease where the immune system attacks the communication between nerves and muscles, causing weakness. It often affects the muscles used for eye movement, facial ...

Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patientsReal-world evidence and long-term data reinforce VYVGART’s sustained ...

Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD, focus on the best and most effective methods of engaging patients who have ...

Temple University is granted summary judgment on the ADA retaliation claim of an assistant professor suffering from myasthenia gravis who was denied tenure, because the discrimination complaint he ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will present more than 30 ...